George Elston
Director of Finance/CFO at EYEPOINT PHARMACEUTICALS, INC.
Net worth: 901 357 $ as of 2024-03-30
Profile
George O.
Elston founded Chatham Street Partners in 2010, where he worked as Managing Partner.
Mr. Elston also currently works at db-X ETF Trust, as Independent Trustee from 2010 and EyePoint Pharmaceuticals, Inc., as Chief Financial Officer & Executive Vice President from 2023.
Mr. Elston also formerly worked at Enzyvant, Inc., as President & Chief Executive Officer from 2018 to 2019, Oncology Venture US, Inc., as President & Chief Executive Officer from 2017 to 2018, AVANT Immunotherapeutics, Inc., as Director in 2008, Celldex Therapeutics, Inc. (Old), as Director from 2004 to 2008, Celldex Therapeutics, Inc., as Independent Director from 2008 to 2017, Celldex Research Corp., as Director, C.
R.
Bard, Inc. (New Jersey), as Principal, Catalent JNP, Inc., as Chief Financial Officer, Secretary & Treasurer from 2015 to 2016, Elusys Therapeutics, Inc., as Vice President-Finance from 2000 to 2009, KBI Biopharma, Inc., as Chief Financial Officer & Senior Vice President from 2013 to 2014, Optherion, Inc., as Chief Operating & Financial Officer from 2008 to 2010, Trillium USA, Inc., as Chief Financial Officer, Pricewaterhousecoopers LLC, as Principal, and Enzyvant Therapeutics, Inc., as Chief Financial Officer from 2018 to 2019.
Mr. Elston received his undergraduate degree from Pace University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-08 | 43,607 ( 0.09% ) | 901 357 $ | 2024-03-30 |
George Elston active positions
| Companies | Position | Start |
|---|---|---|
| EYEPOINT PHARMACEUTICALS, INC. | Director of Finance/CFO | 2019-11-13 |
| db-X ETF Trust | Director/Board Member | 2010-09-30 |
Former positions of George Elston
| Companies | Position | End |
|---|---|---|
Enzyvant Therapeutics, Inc.
 Enzyvant Therapeutics, Inc. BiotechnologyHealth Technology Enzyvant Therapeutics, Inc. develops biopharmaceutical products. It focuses on developing transformative therapies for rare diseases with high unmet needs. The company is headquartered in Cambridge, MA. | Director of Finance/CFO | 2019-08-31 |
Enzyvant, Inc.
 Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The private company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Chief Executive Officer | 2019-08-31 |
Oncology Venture US, Inc.
 Oncology Venture US, Inc. Miscellaneous Commercial ServicesCommercial Services Oncology Venture US, Inc. develops therapies for cancer treatment. The company is headquartered in Cambridge, MA. | Chief Executive Officer | 2018-09-30 |
| CELLDEX THERAPEUTICS, INC. | Director/Board Member | 2017-06-14 |
| JUNIPER PHARMACEUTICALS INC | Director of Finance/CFO | 2016-12-30 |
Training of George Elston
| Pace University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| EYEPOINT PHARMACEUTICALS, INC. | Health Technology |
| CELLDEX THERAPEUTICS, INC. | Health Services |
| Private companies | 15 |
|---|---|
C. R. Bard, Inc. (New Jersey)
 C. R. Bard, Inc. (New Jersey) Medical SpecialtiesHealth Technology C. R. Bard, Inc. engages in designing, development, manufacturing, packaging, distribution, and sales of medical, surgical, diagnostic, and patient care devices. It sells its products to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities. The company was founded by Charles Russell Bard in 1907 and is headquartered in Franklin Lakes, NJ. | Health Technology |
Catalent JNP, Inc.
 Catalent JNP, Inc. Pharmaceuticals: MajorHealth Technology Catalent JNP, Inc. engages in the research and development of drugs and therapeutics. It offers analytical characterization and pre-formulation testing; formulation development; and clinical manufacturing of capsules and tablets. The company was founded in December 1986 and is headquartered in Somerset, NJ. | Health Technology |
AVANT Immunotherapeutics, Inc.
 AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Health Technology |
Celldex Therapeutics, Inc. (Old)
 Celldex Therapeutics, Inc. (Old) BiotechnologyHealth Technology Celldex Therapeutics, Inc. discovers, develops and commercialized novel immunotherapeutics. It offers treatment for cancer, infectious diseased and immune system disorders. The company was founded in May, 2003 and is headquartered in Philipsburg, NJ. | Health Technology |
Elusys Therapeutics, Inc.
 Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Health Technology |
KBI Biopharma, Inc.
 KBI Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services KBI Biopharma, Inc. provides drug development and contract manufacturing services. It helps client partners accelerate and optimize drug development and manufacturing programs by offering an extensive suite of expert development and manufacturing services. The firm offers services to global pharmaceutical and biotechnology companies, and academic and non-profit organizations. The company was founded in 1996 and is headquartered in Durham, NC. | Commercial Services |
Optherion, Inc.
 Optherion, Inc. Medical SpecialtiesHealth Technology Optherion, Inc. develops therapeutic products. It develops products to diagnose and treat dry and wet Age-related Macular Degeneration and other chronic diseases involving the alternative complement system. The company was founded by Gregory S. Hageman, David I. Scheer and Sandy Gordon in 2005 and is headquartered in New Haven, CT. | Health Technology |
| db-X ETF Trust | Miscellaneous |
| Trillium USA, Inc. | Utilities |
Celldex Research Corp.
 Celldex Research Corp. Miscellaneous Commercial ServicesCommercial Services Celldex Research Corp. engages in provision of biological research and development. The company is headquartered in Phillipsburg, NJ. | Commercial Services |
| Pricewaterhousecoopers LLC | |
| Chatham Street Partners | |
Oncology Venture US, Inc.
Oncology Venture US, Inc. Miscellaneous Commercial ServicesCommercial Services Oncology Venture US, Inc. develops therapies for cancer treatment. The company is headquartered in Cambridge, MA. | Commercial Services |
Enzyvant, Inc.
Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The private company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Health Technology |
Enzyvant Therapeutics, Inc.
Enzyvant Therapeutics, Inc. BiotechnologyHealth Technology Enzyvant Therapeutics, Inc. develops biopharmaceutical products. It focuses on developing transformative therapies for rare diseases with high unmet needs. The company is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- George Elston
